Juan Camilo Arjona Ferreira - Sep 27, 2021 Form 4 Insider Report for Myovant Sciences Ltd. (MYOV)

Role
Chief Medical Officer
Signature
/s/ Matthew Lang, Attorney-in-fact
Stock symbol
MYOV
Transactions as of
Sep 27, 2021
Transactions value $
-$115,780
Form type
4
Date filed
9/29/2021, 04:12 PM
Previous filing
Aug 31, 2021
Next filing
Oct 7, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYOV Common Shares Options Exercise $54.5K +7K +4.09% $7.78 178K Sep 27, 2021 Direct
transaction MYOV Common Shares Sale -$170K -7K -3.93% $24.32 171K Sep 27, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MYOV Stock Option (Right to Buy) Options Exercise $0 -7K -4.21% $0.00 159K Sep 27, 2021 Common Shares 7K $7.78 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a 10b5-1 trading plan.
F2 The shares were sold at prices ranging from $24.01 to $24.96. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.